You are here:

Forthcoming Submission: lutetium 177Lu oxodotreotide (Lutathera)

Indication: Unresectable or metastatic, progressive, well differentiated (G1 and G2) somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults.

Drug Details

Drug Name: lutetium 177Lu oxodotreotide (Lutathera)
Drug Manufacturer: Advanced Accelerator Applications
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
2/04/2018
SMC Meeting Date: Q2 2018
Advice Due: Q3 2018

Back